BMO Capital Sticks to Its Buy Rating for NuVasive

By Ryan Adsit

BMO Capital analyst Joanne Wuensch reiterated a Buy rating on NuVasive (NASDAQ: NUVA) on December 12 and set a price target of $70. The company’s shares closed yesterday at $59.16.

According to, Wuensch is a 4-star analyst with an average return of 8.0% and a 65.1% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Baxter International.

Currently, the analyst consensus on NuVasive is Strong Buy and the average price target is $69.80, representing a 18.0% upside.

In a report released yesterday, BTIG also assigned a Buy rating to the stock with a $74 price target.

The company has a one-year high of $81.68 and a one-year low of $49.25. Currently, NuVasive has an average volume of 1.11M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NuVasive, Inc. is medical device company, which engages in the development of minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. It offers cervical and spine fusion surgery, cervical plating, and posterior fixation products. The company was founded by Alexis V.